Zurich Cantonal Bank’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.17M | Buy |
94,838
+8,809
| +10% | +$464K | 0.01% | 683 |
|
|
2026
Q1 | $4.09M | Buy |
+86,029
| New | +$4.54M | 0.01% | 723 |
|
|
2025
Q4 | – | Sell |
-32,156
| Closed | -$1.93M | – | 2799 |
|
|
2025
Q3 | $2.08M | Buy |
32,156
+8,027
| +33% | +$461K | ﹤0.01% | 900 |
|
|
2025
Q2 | $1.17M | Buy |
24,129
+1,036
| +4% | +$40.1K | ﹤0.01% | 1145 |
|
|
2025
Q1 | $786K | Buy |
23,093
+876
| +4% | +$37.1K | ﹤0.01% | 1312 |
|
|
2024
Q4 | $874K | Buy |
22,217
+645
| +3% | +$30.5K | ﹤0.01% | 1264 |
|
|
2024
Q3 | $1.01M | Buy |
21,572
+98
| +0.5% | +$4.97K | ﹤0.01% | 1119 |
|
|
2024
Q2 | $1.16M | Buy |
21,474
+1,884
| +10% | +$109K | ﹤0.01% | 997 |
|
|
2024
Q1 | $1.34M | Sell |
19,590
-969
| -5% | -$69.4K | ﹤0.01% | 920 |
|
|
2023
Q4 | $1.29M | Buy |
20,559
+2,032
| +11% | +$112K | ﹤0.01% | 927 |
|
|
2023
Q3 | $841K | Buy |
18,527
+1,879
| +11% | +$97K | ﹤0.01% | 1066 |
|
|
2023
Q2 | $935K | Buy |
16,648
+842
| +5% | +$47.8K | ﹤0.01% | 969 |
|
|
2023
Q1 | $715K | Buy |
15,806
+931
| +6% | +$45.2K | ﹤0.01% | 1081 |
|
|
2022
Q4 | $605K | Buy |
14,875
+1,097
| +8% | +$58.2K | ﹤0.01% | 1140 |
|
|
2022
Q3 | $900K | Sell |
13,778
-34,427
| -71% | -$2.49M | 0.01% | 879 |
|
|
2022
Q2 | $2.93M | Sell |
48,205
-3,612
| -7% | -$212K | 0.02% | 589 |
|
|
2022
Q1 | $3.25M | Sell |
51,817
-2,074
| -4% | -$130K | 0.02% | 616 |
|
|
2021
Q4 | $4.08M | Buy |
53,891
+7,627
| +16% | +$666K | 0.02% | 586 |
|
|
2021
Q3 | $5.18M | Buy |
46,264
+831
| +2% | +$104K | 0.03% | 503 |
|
|
2021
Q2 | $7.36M | Buy |
45,433
+6,066
| +15% | +$738K | 0.04% | 392 |
|
|
2021
Q1 | $4.8M | Buy |
39,367
+3,907
| +11% | +$590K | 0.03% | 493 |
|
|
2020
Q4 | $5.43M | Buy |
35,460
+10,941
| +45% | +$1.29M | 0.03% | 463 |
|
|
2020
Q3 | $2.05M | Buy |
24,519
+1,074
| +5% | +$95.3K | 0.01% | 686 |
|
|
2020
Q2 | $1.72M | Buy |
23,445
+4,406
| +23% | +$258K | 0.01% | 674 |
|
|
2020
Q1 | $807K | Sell |
19,039
-360
| -2% | -$18.6K | 0.01% | 781 |
|
|
2019
Q4 | $1.18M | Buy |
19,399
+16,529
| +576% | +$902K | 0.01% | 787 |
|
|
2019
Q3 | $118K | Buy |
2,870
+343
| +14% | +$16.4K | ﹤0.01% | 1524 |
|
|
2019
Q2 | $119K | Hold |
2,527
| – | – | ﹤0.01% | 1513 |
|
|
2019
Q1 | $90K | Hold |
2,527
| – | – | ﹤0.01% | 1640 |
|
|
2018
Q4 | $72K | Sell |
2,527
-300
| -11% | -$10.4K | ﹤0.01% | 1800 |
|
|
2018
Q3 | $125K | Hold |
2,827
| – | – | ﹤0.01% | 1586 |
|
|
2018
Q2 | $166K | Buy |
2,827
+1,127
| +66% | +$64.2K | ﹤0.01% | 1355 |
|
|
2018
Q1 | $78K | Sell |
1,700
-3,600
| -68% | -$149K | ﹤0.01% | 1755 |
|
|
2017
Q4 | $124K | Hold |
5,300
| – | – | ﹤0.01% | 1459 |
|
|
2017
Q3 | $95K | Buy |
+5,300
| New | +$96.1K | ﹤0.01% | 1436 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Zurich Cantonal Bank's CRSP Position: Q2 2026 in Review
Zurich Cantonal Bank increased its CRISPR Therapeutics (CRSP) stake by 10% in Q2 2026, buying an estimated $464K and bringing the position to 94,838 shares worth $5.17M. The position accounts for 0.01% of the portfolio, ranked #683.
Zurich Cantonal Bank first reported a position in CRSP in Q3 2017 and has held it in 35 quarters since. The position peaked at $7.36M in Q2 2021. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Zurich Cantonal Bank held 94,838 shares of CRISPR Therapeutics worth $5.17M as of Q2 2026.
- Zurich Cantonal Bank bought 8,809 CRISPR Therapeutics shares in Q2 2026, an estimated $464K.
- CRISPR Therapeutics made up 0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #683 holding.
- Zurich Cantonal Bank first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 35 quarters since.
- Zurich Cantonal Bank's CRISPR Therapeutics position peaked at $7.36M in Q2 2021.
- 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.